TropIQ Health Sciences – Mosquito infectious disease research platform
TropIQ Health Sciences operates a technology platform for the discovery and development of molecules to combat insect-borne infectious diseases. TropIQ combines world-class parasitological and entomological expertise with state of the art drug discovery technologies. Through this combination, TropIQ is uniquely positioned to accelerate the development of novel medicines, vaccines and vector control measures. The company was founded in 2011 as a spin-off of the Radboud University Nijmegen Medical Center in the Netherlands.
(TropIQ’s webiste is HERE)
MISSION
Vector-borne diseases
Vector-borne diseases are infectious diseases transmitted by insects such as mosquitoes, flies and ticks. Together they threaten half of the world’s population and cause more than 1 million deaths annually. People in the poorest countries are the most vulnerable. For example, malaria leads to over 250 million clinical cases and causes 600,000 deaths per year, mainly children under five years of age in sub-Saharan Africa. The disease is caused by a parasite and is transmitted by mosquitoes.
Vision
It is TropIQ’s vision that there is a dynamic relationship between poverty and health. Many infectious diseases are the direct result of living conditions induced by poverty. In turn, these diseases exacerbate the impoverished status as they reduce productivity and economic prospects.
Mission
TropIQ aims at creating better opportunities for people by improving their health. To this end it provides enabling technology for the elimination of infectious diseases.
RESEARCH
Technology
TropIQ’s technology platform includes facilities for semi-automated cell and parasite culture, a vector lab for entomological experiments and liquid dispensing and state-of-the-art signal detection equipment. TropIQ has developed a unique barcoded live insect screening technology for discovery of novel vector control agents (insecticides, repellents, attractants) and malaria transmission-blocking molecules.
Services
TropIQ provides services and reagents to accelerate your research. These include:
- Barcoded microtiter-plate based live insect screening assays for discovery of vector control agents and antimalarials
- Insecticide sensitivity screens in systemic and contact mode
- Malaria life cycle fingerprinting. IC50 measurements againstall P. falciparum stages, including gametocytes, oocysts, sporozoites and liver stage par asites.
- Sensitive mix-and-measure immunoassays to determine malaria immune responses
- Supply of wildtype and transgenic GFP/luciferase parasite stages for assaydevelopment and assay calibration
- Supply of monoclonal antibodies against various epitopes of sexual stage antigens
Pfs25
| mAb code | Antigen | Epitope | IgG type | B cell species | Myeloma | Transmission blocking | Western blot (native) | Reference |
| 32F81 | Pfs25 | 1 | IgG1 | Mus musculus | P3/X63-Ag8.653 | + | + | Vermeulen et al., J. Exp. Med. 162, 1460-1476 |
| 32F71 | Pfs25 | 2 | IgG2a | Mus musculus | P3/X63-Ag8.653 | – | + | Vermeulen et al., J. Exp. Med. 162, 1460-1476 |
| mAb code | Antigen | Epitope | IgG type | B cell species | Myeloma | Transmission blocking | Western blot (native) | Reference |
| 85RF45.1 | Pfs48/45 | 1a | IgG1 | Rattus norvegicus | Y3-Ag1.2.3 | + | + | Roeffen et al., Exp. Parasitol 97, 45-49 |
| 85RF45.2b | Pfs48/45 | 2b | IgG1 | Rattus norvegicus | Y3-Ag1.2.3 | – | + | Roeffen et al., Exp. Parasitol 97, 45-49 |
| 85RF45.3 | Pfs48/45 | 3 | IgG1 | Rattus norvegicus | Y3-Ag1.2.3 | – | + | Roeffen et al., Exp. Parasitol 97, 45-49 |
| 85RF45.5 | Pfs48/45 | 5b | IgG2a | Rattus norvegicus | Y3-Ag1.2.3 | + | + | Roeffen et al., Exp. Parasitol 97, 45-49 |
| mAb code | Antigen | Epitope | IgG type | B cell species | Myeloma | Transmission blocking | Western blot (native) | Reference |
| 18F25 | Pfs230 | 1 | IgG1 | Mus musculus | P3/X63-Ag8.653 | – | + | Roeffen et al., Exp. Parasitol. 80, 15-26 |
| 63F2A2_IgG1 | Pfs230 | 2 | IgG1 | Mus musculus | P3/X63-Ag8.653 | – | + | Roeffen et al., Exp. Parasitol. 80, 15-26 |
| 63F2A2_IgG2a | Pfs230 | 2 | IgG2a | Mus musculus | P3/X63-Ag8.653 | + | + | Roeffen et al., Exp. Parasitol. 80, 15-26 |
Research
TropIQ’s technology platform serves a proprietary drug discovery program focused on novel anti-malarials and vector control agents. Our pantothenamide antimalarial drug discovery program aims at a first-in-human study in 2018.
若您對於頁面產品有任何疑問及需求，請與我們聯繫
Tokyo Future Style Taiwan
info-tw@tokyofuturestyle.com
TEL : +886-2-25785958 FAX : +886-2-25789826
